Rapport Therapeutics (NASDAQ:RAPP - Get Free Report)'s share price gapped up prior to trading on Monday . The stock had previously closed at $19.00, but opened at $19.61. Rapport Therapeutics shares last traded at $19.62, with a volume of 495 shares.
Analyst Ratings Changes
Several research analysts have recently weighed in on the company. TD Cowen started coverage on Rapport Therapeutics in a research note on Tuesday, July 2nd. They issued a "buy" rating for the company. Stifel Nicolaus started coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 2nd. They set a "buy" rating and a $35.00 target price on the stock. Finally, Jefferies Financial Group started coverage on shares of Rapport Therapeutics in a report on Tuesday, July 2nd. They set a "buy" rating and a $35.00 price target on the stock.
Read Our Latest Analysis on Rapport Therapeutics
Rapport Therapeutics Stock Performance
The business's 50-day moving average is $21.50.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($1.02). On average, equities analysts forecast that Rapport Therapeutics will post -3.46 EPS for the current fiscal year.
Insider Activity at Rapport Therapeutics
In other Rapport Therapeutics news, Director James Healy purchased 44,032 shares of the firm's stock in a transaction that occurred on Monday, July 1st. The shares were bought at an average price of $24.52 per share, with a total value of $1,079,664.64. Following the completion of the purchase, the director now directly owns 40,851 shares in the company, valued at $1,001,666.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Institutional Trading of Rapport Therapeutics
A number of large investors have recently modified their holdings of RAPP. ARCH Venture Management LLC purchased a new stake in shares of Rapport Therapeutics in the 2nd quarter worth approximately $86,730,000. Johnson & Johnson bought a new position in shares of Rapport Therapeutics during the 2nd quarter worth approximately $58,105,000. Sofinnova Investments Inc. purchased a new position in shares of Rapport Therapeutics in the 2nd quarter valued at approximately $45,393,000. Perceptive Advisors LLC purchased a new position in Rapport Therapeutics in the 2nd quarter worth $17,403,000. Finally, Logos Global Management LP purchased a new stake in shares of Rapport Therapeutics in the 2nd quarter valued at $4,859,000.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
See Also
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
